Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases

Stopped The study was early terminated considering the inability to enroll the required study population.

Conditions

• COVID-19

Interventions

• BIOLOGICAL: CpG 1018/Alum-adjuvanted SCB-2019 vaccine
• BIOLOGICAL: Havrix
• OTHER: Placebo; 0.9% saline

Sponsor

Clover Biopharmaceuticals AUS Pty